MetaCap

60 Degrees Pharmaceuticals Inc. (SXTP)

NASDAQ: SXTPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.4682-0.0318 (-6.36%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SXTP stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.34
52-week range
0.46 – 8.62
Day range
0.46 – 0.4998
Volume / Avg
51.29K / 407.29K
Beta
—

52-week range

$0.46$8.62

SXTP stock today

Shares of 60 Degrees Pharmaceuticals (SXTP) finished lower on Nov 20 at $0.4682, a drop of 6.36% or $0.0318 per share, versus the S&P 500's 3.70% decline. Trading was light, with 51.29K shares changing hands, about 13% of the average daily volume. Shares are 94.6% below their 52-week high of $8.62 and 1.8% above the 52-week low of $0.46, near the bottom of the past year's range.

60 Degrees Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.34), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About 60 Degrees Pharmaceuticals

Company profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Geoffrey Stuart Dow Ph.D.
Headquarters
Washington, DC
Employees
3
IPO year
2023

Financial highlights

Full financials

In fiscal 2025, 60 Degrees Pharmaceuticals generated $1.0 million in revenue, up 65.5% from fiscal 2024, its 3rd consecutive year of revenue growth. 60 Degrees Pharmaceuticals reported a net loss of $7.4 million, compared with a loss of $7.9 million a year earlier. Gross margin was 22.3% (down from 36.7%) and operating margin -771.6%.

60 Degrees Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$1.01M$607.57K$253.57K$223.21K
Growth+65.49%+139.61%+13.60%—
Net income$-7.37M$-7.95M$-3.77M$-6.18M
EPS (diluted)$-11.73$-74.17$-59.18$-2.61

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$3.70+690.26%

  • Strong buy 0
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.75 vs $-0.73
Surprise
-2.74%

SXTP news

All SXTP news

60 Degrees Pharmaceuticals peers

Health Care sector
SXTP peer companies
CompanyPrice% ChgMarket capCompare
KAPAKairos Pharma Ltd.0.4359-4.62%$2.04Mvs SXTP
ENLVEnlivex Ltd.1.05-11.76%$2.01Mvs SXTP
LABTLakewood-Amedex Biotherapeutics Inc.0.2449+15.03%$2.19Mvs SXTP
REVBRevelation Biosciences Inc.3.50-5.15%$1.99Mvs SXTP
DCOYDecoy Therapeutics Inc.0.8294-4.68%$1.98Mvs SXTP
GNPXGenprex Inc.1.45-13.17%$1.94Mvs SXTP
EOCNEocene Ltd.1.78+1.73%$1.90Mvs SXTP
ERNAErnexa Therapeutics Inc.1.36-16.56%$2.30Mvs SXTP

Indexes, lists and sector

60 Degrees Pharmaceuticals stock FAQ

What is 60 Degrees Pharmaceuticals's stock price today?

SXTP last traded at $0.4682 as of Nov 20, 4:00 PM EST, down 6.36% on the day. Prices are delayed at least 15 minutes.

Who is 60 Degrees Pharmaceuticals's CEO?

Dr. Geoffrey Stuart Dow Ph.D. is the chief executive officer of 60 Degrees Pharmaceuticals Inc., which has about 3 employees.

What is the SXTP 52-week high?

The 52-week high for SXTP is $8.62 and the 52-week low is $0.46. The stock is currently 94.6% below its high.

Compare SXTP